Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23328| Title: | Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. | Austin Authors: | Tiong, Ing S ;Dillon, Richard;Ivey, Adam;Teh, Tse-Chieh;Nguyen, Phillip;Cummings, Nicholas;Taussig, David C;Latif, Annie-Louise;Potter, Nicola E;Runglall, Manohursingh;Russell, Nigel H;Raj, Kavita;Schwarer, Anthony P ;Fong, Chun Yew ;Grigg, Andrew P ;Wei, Andrew H | Affiliation: | Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia Alfred Hospital and Monash University, Melbourne, Victoria, Australia Box Hill Hospital, Melbourne, Victoria, Australia Guy's and St Thomas' Hospitals, London, UK Department of Medical and Molecular Genetics, King's College, London, UK Department of Haematology, Royal Marsden Hospital, London, UK NHS Greater Glasgow and Clyde, Glasgow, UK Department of Medical and Molecular Genetics, King's College, London, UK NIHR Comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital, London, UK Guy's and St Thomas' Hospitals, London, UK Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia |
Issue Date: | Mar-2021 | Date: | 2020-05-26 | Publication information: | British Journal of Haematology 2021; 192(6): 1026-1030 | Abstract: | Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23328 | DOI: | 10.1111/bjh.16722 | ORCID: | 0000-0001-7417-4343 0000-0001-9333-5296 |
Journal: | British Journal of Haematology | PubMed URL: | 32458446 | Type: | Journal Article | Subjects: | AML MRD NPM1 venetoclax |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.